Timothy P. Adams
Known title: DirectorCIK: 0002035070
Timothy P. Adams's purchase track record
How the stock did after each of Timothy P. Adams's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since October 31, 2024
Stock higher 6 months later
25%
3 months: 50%
Median 6-month return
-12.2%
3 months: +62.3%
Beat the S&P 500
25%
median -19.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/6/2026 | SSII | $1.20M | -14.9% | -23.2% | +14.5% |
| 2/14/2025 | SSII | $1.72M | -1.6% | -33.1% | +5.5% |
| 12/10/2024 | SSII | $2.05M | +135.3% | -1.2% | +0.1% |
| 10/31/2024 | SSII | $2.04M | +126.3% | +170.1% | -1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SSII | ▲ Buy | Open Market | 300,000 | $1.2M | 3/6/2026 | View on chart |
| SSII | ▲ Buy | Open Market | 1,250,000 | $1.7M | 2/14/2025 | View on chart |
| SSII | ▲ Buy | Open Market | 1,400,620 | $2.0M | 12/10/2024 | View on chart |
| SSII | ▲ Buy | Open Market | 1,399,595 | $2.0M | 10/31/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SSII Submits FDA Response for SSi Mantra Robotic System
SS Innovations International has submitted a response to the FDA regarding its 510(k) submission for the SSi Mantra surgical robotic system. This regulatory update addresses a request for additional information, marking a step in the approval process for the company's key product. Separately, Zacks initiated coverage of the stock with a neutral recommendation.
SSII Submits FDA Response for SSi Mantra Robotic System. SS Innovations International has submitted a response to the FDA regarding its 510(k) submission for the SSi Mantra surgical robotic system. This regulatory update addresses a request for additional information, marking a step in the approval process for the company's key product. Separately, Zacks initiated coverage of the stock with a neutral recommendation.